The Role Rapid Acceleration of Diagnostics Tech Continues to Play in the Covid-19 Pandemic and Next Steps - CIMIT MAIN

Responsive Image
The FDA has approved the first rapid hepatitis C virus test for the U.S. market that can be used in patient care settings. The test, which was validated in part by the NIH RADx Tech program with funding from CDC, can provide results in about one hour, meaning patients with a positive test can begin treatment right away. We're honored to have been a part of the journey behind this important milestone! 

Learn more about this game changer for hepatitis C diagnosis >

Programs and Offerings

News and Events

null The Role Rapid Acceleration of Diagnostics Tech Continues to Play in the Covid-19 Pandemic and Next Steps

thumbnail

The Role Rapid Acceleration of Diagnostics Tech Continues to Play in the Covid-19 Pandemic and Next Steps

Rapid Acceleration of Diagnostics (RADx) Tech is a National Institutes of Health (NIH)-funded program launched on 29 April 2020, to accelerate commercialization of novel lab-based, point-of-care, and home-based tests to diagnose infection with SARS-CoV-2, the virus that causes COVID-19. RADx Tech was implemented and coordinated by the Consortia for Improving Medicine with Innovation & Technology (CIMIT) in its role as the Coordinating Center for the Point-of-Care Technologies Research Network (POCTRN) in conjunction with the NIH’s National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the four POCTRN Centers.

Read the full article in the Expert Review of Molecular Diagnostics >

Connect with Us

Our Lasting Impact

As an early pioneer in managing translational research, Cimit has directly supported over 1,200 innovator teams and reviewed or consulted on over 5,000 ideas since our founding in 1998.

We work collaboratively with healthtech innovators, entrepreneurs, and institutions to ultimately make a positive impact on patient care across the globe. We streamline pathways to progress through our efficient processes, established systems, and unparalleled market expertise.